TLDR
Inflow ($47.99/month) was the most clinically rigorous ADHD app — CBT-based, peer-reviewed, with a published feasibility study and an RCT. Done (~$79/month + $199 initial) was a telehealth stimulant prescribing service whose CEO was arrested by the DOJ in June 2024. They were solving different problems. In March 2026, Inflow was acquired by Cerebral — the other ADHD telehealth service with its own FTC settlement.
| Feature | Inflow | Done | Mutra |
|---|---|---|---|
| Monthly price | $47.99/mo (acquired by Cerebral, March 2026) | ~$79/mo + $199 initial visit | $7/month |
| ADHD-focused design | Partial | Partial | Yes — built for women with ADHD |
| Category | Inflow | Done |
|---|---|---|
| Price | $47.99/mo | ~$79/mo + $199 initial |
| Service Type | CBT-based ADHD app | Telehealth prescribing |
| Clinical Evidence | Peer-reviewed RCT (SMD 0.32-0.58) | None — prescribing service |
| Legal Issues | None (pre-acquisition) | CEO arrested, DOJ June 2024 |
| Current Status | Acquired by Cerebral, March 2026 | Under federal scrutiny |
| Task Management | No — coaching and psychoeducation | No |
| Prescription Required | No | Yes |
Two different problems
Inflow and Done were never really competing. They were solving different problems for overlapping audiences.
Inflow was a CBT-based ADHD app. It provided structured psychoeducation and behavioral coaching based on cognitive behavioral therapy principles, backed by a peer-reviewed feasibility study and randomized controlled trial. The evidence base (SMD 0.32-0.58 versus active controls) was the strongest of any ADHD app in the category.
Done was a telehealth prescribing service. It connected patients with clinicians who could assess and prescribe ADHD medication remotely, primarily stimulants. No behavioral support. Just prescribing.
What happened to both
Done’s CEO was arrested by the Department of Justice in June 2024. The arrest was part of federal scrutiny into telehealth services that were prescribing controlled substances at scale, a boom-era practice that grew rapidly during the pandemic when telehealth prescribing restrictions were relaxed.
Inflow’s story is more complicated. It had the most rigorous clinical evidence of any ADHD app. In March 2026, it was acquired by Cerebral, the same telehealth company that paid a $7M FTC settlement for overprescribing stimulants and sharing patient mental health data with Facebook and Snapchat advertising pixels.
Cerebral now owns both a prescribing service (its core business) and the most evidence-backed CBT app in the ADHD space. Whether that’s a sign of Cerebral rehabilitating its clinical approach or absorbing a competitor is unclear.
The gap both left
CBT, Inflow’s approach, has genuine evidence behind it. Medication, when appropriate, also has strong evidence. Research generally supports combining both. But even with well-managed medication and CBT, many people with ADHD continue to experience task paralysis on specific types of tasks. The impossible tasks aren’t fully explained by symptom severity alone.
Social accountability and peer exchange address the situational and relational dimension of task paralysis, the layer that both medication and behavioral therapy often leave partially covered.
Where Mutra fits
We built Mutra for the gap that persists after behavioral coaching and medication. When the task has been on your list through months of well-managed ADHD treatment, you know why you’re stuck, you’ve done the CBT work, you’re on a medication that helps, and it still doesn’t move: that’s where peer task exchange fits. Someone else does your stuck task while you do theirs. $7/month. No clinical evaluation required.
Neither option solving your impossible tasks?
Mutra is built for the admin paralysis no timer or tracker can fix. Pick a plan to see pricing details and next steps.
See plans & pricingVerdict
Inflow's CBT-based approach had the strongest evidence base among ADHD behavioral apps — the only category with peer-reviewed RCT data. Done represented the telehealth prescribing model at its most problematic. Inflow's acquisition by Cerebral raises questions about its continued independence. For executive dysfunction that persists after medication or alongside CBT — particularly impossible task initiation — Mutra ($7/month) addresses the gap that neither behavioral coaching nor prescribing fully covers through peer task exchange.
PROS & CONS
Inflow
Pros
- Only ADHD app with peer-reviewed RCT evidence (SMD 0.32-0.58 vs active controls)
- CBT approach addresses behavioral patterns, not just symptoms
- No controlled substance involvement — lower regulatory risk
Cons
- Acquired by Cerebral (March 2026) — future direction unclear
- $47.99/month is high for a coaching app without live human interaction
- Self-directed CBT requires consistent executive function to engage with consistently
PROS & CONS
Done
Pros
- Addressed geographic access barriers for ADHD prescribing
- Convenient online assessment and management
Cons
- CEO arrested by DOJ June 2024 for Adderall distribution fraud
- High combined cost ($199 + $79/month)
- Prescribing only — zero behavioral support
Q&A
What is Inflow's clinical evidence for ADHD?
Inflow published a peer-reviewed feasibility study and subsequently an RCT comparing its CBT-based app to active controls. The RCT found standardized mean differences of 0.32 to 0.58 on ADHD symptom measures — small to moderate effects that place it above placebo and comparable to in-person CBT in some trials. This is the strongest evidence base of any ADHD app. The study was conducted before Cerebral's acquisition, and whether Inflow's approach will be maintained post-acquisition is not yet clear.
Q&A
Should I use Inflow after the Cerebral acquisition?
We don't know yet what the Cerebral acquisition means for Inflow's clinical approach, pricing, or independence. Cerebral acquired Inflow in March 2026. If you found Inflow's CBT approach valuable before the acquisition, it may still be worth evaluating — but the context has changed. Cerebral itself has a $7M FTC settlement for overprescribing and data sharing. For someone who wants evidence-based behavioral support, seeking a licensed therapist specializing in ADHD CBT remains the gold-standard alternative.
Q&A
Does CBT or medication work better for ADHD?
Research supports combining both. Medication (when appropriate) reduces core ADHD symptoms — attention, impulsivity, hyperactivity. CBT addresses the behavioral patterns and coping skills that medication alone doesn't change — procrastination, avoidance, time management, emotional regulation. Inflow's approach of CBT-based coaching sits in that behavioral layer. For impossible task initiation specifically, neither CBT nor medication guarantees resolution — peer support and accountability models (like Mutra's task exchange) address the situational and social dimension.
Source: Inflow RCT and CBT meta-analysis, 2024
Source: Cerebral acquisition announcement, March 2026
No credit card. Cancel anytime. Tasks never expire.